Our group has described subclinical cognitive alterations [8], structural cerebral differences (in both grey and white matter) [9] and increased plasma NfL levels (a biomarker for brain damage) [10] in patients with T1D with IAH (T1D‐IAH). The gene discussed is NEFL; the disease is type 1 diabetes mellitus.